Background/Aims: The current study aimed to investigate the role by which fibronectin 1 (FN1) influences the cell cycle, senescence and apoptosis in human glioma cells through the PI3K/ AKT signaling pathway. Methods: Differentially expressed genes (DEGs) were identified based on gene expression data (GSE12657, GSE15824 and GSE45921 datasets) and probe annotation files from Gene Expression Omnibus. The DEGs were identified in connection with gene ontology (GO) enrichment analysis and with the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The positive expression of the FN1 protein was detected by immunohistochemistry. The glioma cell lines U251 and T98G were selected and assigned into blank, negative control (NC) and siRNA-FN1 groups. A dual luciferase reporter gene assay was used to investigate the effects of FN1 on transcriptional activity through the PI3K/AKT signaling pathway. An MTT assay was applied for the detection of cell proliferation, while flow cytometry was employed for cell cycle stage and cellular apoptosis detection. β-galactosidase staining was utilized to detect cellular senescence, a scratch test was applied to evaluate cell migration, and a transwell assay was used to analyze cell invasion. Western blotting and qRT-PCR methods were used to detect the protein and mRNA expression levels, respectively, of the FN1 gene and the related genes in the PI3K/AKT pathway (PI3K, AKT and PTEN), the cell cycle (pRb, CDK4 and Cyclin D1) and cell senescence (p16 and p21) among the collected tissues and cells. Results: GSE12657 profiling revealed FN1 to be the most upregulated gene in glioma.
Introduction
Gliomas are primary malignant brain tumors that arise from glial or precursor cells and include astrocytoma, glioblastoma, oligodendroglioma, ependymoma, mixed glioma, and malignant glioma [1, 2] . The prognosis of glioma is largely contingent on the histology and tumor grade. Glioblastoma (WHO grades III/IV) has the worst prognosis, while lowgrade glioma (WHO grades I/II) and oligodendroglioma tend to have better outcomes when treated with chemotherapy and/or radiotherapy [3] . Clinical studies have indicated that the incidence of anaplastic astrocytoma and glioblastoma increases with age, as older patients represent a risk group with high susceptibility to pathologically confirmed glioma. Generally, with the exception of pilocytic astrocytoma, gliomas appear to be more common among males than females [4] . At present, treatment efforts directed at developing targeted therapies for gliomas have been hindered, mainly due to glioma being a molecularly distinct disease entity that may manifest various clinical effects. Furthermore, treatment resistance remains a common challenge and is associated with the high recurrence rates [5] .
Several molecular biomarkers that have been shown to regulate tumor progression and survival, such as methylguanine methyltransferase, PIK3R1 and epidermal growth factor receptor (EGFR), continue to be assessed as potential targets for the management of glioma, [6] . The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/phosphatase and tensin homologue (PTEN) signaling axis has been verified as an important oncogenic pathway among the dysregulated signaling pathways in glioma. PI3Ks are members of a lipid kinase family. The activation of PI3Ks occurs through growth factor receptors, cell adhesion molecules and G-protein-coupled receptors [7] . AKT, a serine/threonine-specific kinase, is a downstream effector of PI3K that regulates cellular activities, and it has been shown to be a crucial factor in the development of glioma [8, 9] . Emerging evidence from various studies, have revealed that the aberrant activity of PI3K/AKT/ mammalian target of rapamycin (mTOR) acts to facilitate drug-resistant glioma phenotypes, and has been suggested to be among the most responsive pathways in relation to the pharmacological intervention for the treatment of glioma [10] .
Fibronectin (FN) is a glycoprotein with a high molecular weight ranging between 220, 000 and 250, 000. As an adhesive molecule, FN was initially isolated from human plasma and the cell surface of fibroblasts and is present at high levels in the extracellular matrix (ECM) of numerous tumors, including gliomas [11, 12] . Fibronectin 1 (FN1), a member of the FN family, is involved in a variety of cellular processes and in diseases such as cancer, arthritis and atherosclerosis [13] . Several studies have reported that FN modulates the biology of cells through its influence on PI3K/AKT signaling [14, 15] . During the current study, we analyzed existing microarray data and conducted expression analysis in clinical samples and human glioma cell lines to evaluate our hypothesis that FN1 contributes to glioma cell growth, invasion, and survival by activating the PI3K/AKT signaling pathway.
Materials and Methods

Gene expression omnibus (GEO) data sets analysis
Gene expression data (GSE12657, GSE15824 and GSE45921 profiling data) and probe annotation files, which and they were detected by the Human Genome U95 Version 2 Array and the Human Genome U133 Plus 2.0 Array, respectively (Affymetrix Inc., Santa Clara, CA, USA), were downloaded from the GEO database (http://www.ncbi.nlm.nih.gov/geo). Calibration and normalization of the gene profiling data were conducted in concert with the use of the affy package in R software [16] . Next, the expression data were non-specifically filtered using the linear empirical Bayes (EB) approach (limma package) and a t test, and differentially expressed genes (DEGs) were identified [17] . According to the WebGestalt database (http:// www.webgestalt.org), gene ontology (GO) enrichment analysis for 'cellular component', 'molecular function' and 'biological processes' was performed on the DEGs [18] . Pathway enrichment analysis was conducted using the ClusterProfiler package from R software based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.ad.jp/kegg/) to determine the primary DEG-related signaling pathways [19, 20] .
Study subjects
Between June 2012 and October 2016, sixty glioma samples were collected from patients undergoing initial surgical resections at the Xiangya Hospital, Central South University. All collected samples were verified by histopathology, utilizing hematoxylin-eosin (H&E) staining methods. All patients with complete clinicopathological data were initially treated with surgical therapy procedures and had yet to receive any forms of radiotherapy or other therapies prior to surgery. There were 40 males and 20 females between the ages of 27 and 76 years, with an average age of 55 years. There were 28 cases with a tumor diameter less than 4 cm and 32 cases with a tumor diameter larger than or equal to 4 cm. According to the World Health Organization (WHO) classification of tumors of the central nervous system (2007), there were 23 cases of low-grade glioma (I ~ II) and 37 cases of high-grade glioma (II ~ IV). The glioma tissues and normal brain tissues (peritumoral tissue within 2 cm of the tumor edge) were collected and preserved at -80 ºC until further use. All participating patients were provided informed consent documentation. All experiments and protocols of this study were pre-approved by the ethics committee of Xiangya Hospital, Central South University.
Immunohistochemistry Samples (both glioma and normal brain tissues) were fixed with 10% formalin, embedded in paraffin, sliced into 5-μm slices, baked in a 60°C electrothermostat for 8 h, dewaxed with xylene, hydrated with gradient alcohol and washed with phosphate buffer saline (PBS). Next, the slices were incubated in 3% H 2 O 2 at 37°C for 40 min to inactivate endogenous peroxidase. After placing the tissues in 0.01 M citrate buffer for 3 min for antigen retrieval, the slices were left to cool and washed again with PBS. The tissue slices were then blocked in serum at 37°C for 2 h and incubated with rabbit anti-human FN1 primary antibody (1: 250, ab32419, Abcam Inc., Cambridge, MA, USA) at 4°C overnight. PBS was used as the negative control (NC) instead of the primary antibody. After they were washed with PBS, the slices were incubated with biotin-labeled goat anti rabbit conjugated with horseradish peroxidase (HRP) secondary antibody (1:1000, ab6721, Abcam Inc., Cambridge, MA, USA) at 37°C for 30 min. Diaminobenzidine (DAB) (No: DA1010-3, Solarbio Science & Technology Co., Ltd., Beijing, China) was used for developing. Tissue slices were then counterstained with hematoxylin (No: H8070, Solarbio Science & Technology Co., Ltd., Beijing, China) for 10 s, differentiated with hydrochloric alcohol for 2 s, rinsed with running water, dehydrated with gradient alcohol and sealed with neutral balsam. 
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA of the gliomas and the normal brain samples (50 mg) was extracted using an RNA extraction kit (JL1256, Qiagen GmbH, Hilden, Germany). The RNA concentration was detected using an ultraviolet (UV) spectrophotometer (UV-2550, SHIMADZU Co., Ltd, China). Based on information in GenBank, primers for FN1, PI3K, AKT, PTEN, pRb, CDK4, cyclin D1, p16, p21 and glyceraldehyde phosphate dehydrogenase (GAPDH) were designed (Table 1 ) and synthesized by Takara Bio (Shiga, Japan). Reverse transcription of cDNA was completed in accordance with the instructions in the RNA Transcription Kit (DRR037A, Takara Bio, Shiga, Japan) with a reaction volume of 10 μL at 37°C for 15 min and 85°C for 5 s. Next, PCR was performed per the instructions of the SYBR Premix Ex Taq TM Kit (DRR420A, Takara Bio, Shiga, Japan). The total reaction system (20 ]. This method was also applied in cells.
Western blotting
Ninety milligrams of frozen tissue were mixed with 1 mL of prepared radioimmunoprecipitation assay (RIPA) buffer in an ice-bath for 30 min. Tissue homogenates were collected in 1.5 mL centrifuge tube to centrifuge at 12, 000 rpm for 15 min at 4°C. The supernatant was used to detect the protein concentration via a bicinchoninic acid (BCA) kit (BCA1-1KT, Sigma-Aldrich Chemical Company, St Louis MO, USA). Next, 20 μg of protein was added with 2 × sodium dodecyl sulfate (SDS) loading buffer (same volume), boiled for 10 min and placed on ice for 2 min. Then, 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed at a constant voltage of 120 V. After electrophoresis, the proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane for 2 h at 350 mA. The membrane was blocked using 20 mL of Tris-buffered saline with Tween 20 (TBST) containing 5% skimmed milk powder at room temperature for 1 h. The primary antibodies (Abcam Inc., Cambridge, MA, USA), rabbit anti-human FN1 (1:1000, ab32419), PI3K (1:500, ab189403), AKT (1:500, ab8805), PTEN (1:10000, ab32199), pRb (1:000, ab4787), CDK4 (1:2000, ab108357), Cyclin D1 (1:10000, ab134175), p16 (1:1000, ab51243), p21 (1:000, ab109520) and GAPDH (1:2500, ab9485), were added and incubated overnight at 4°C, which was followed by 3 TBST washes (10 min per wash). The secondary antibody, HRP-labeled goat anti-rabbit IgG (1: 2000, ab6721, Abcam Inc., Cambridge, MA, USA), was added for 1 h at room temperature followed by 3 TBST washes (10 min per wash). Electrochemiluminescence (ECL) solution (Pierce, Rockford, IL, USA) was used for 5 min to develop the blot. GAPDH was used as the internal reference, and the relative protein expression is presented by the ratio of the density of the targeted band compared to that of the reference band. This method was also applied to the cells.
Cell culture
Human glioma cell lines (BT325, A172, U251, SHG44 and T98G), purchased from the Shanghai Institutes for Biological Science, Chinese Academy of Sciences, were cultured in Dulbecco's minimum essential medium (DMEM) containing 10% fetal bovine serum (FBS) in an incubator with 5% CO 2 with saturated humidity at 37°C. The culture medium was replaced at 48 h intervals. After cell confluency had reached 80-90%, cell passage was then performed. The previous medium was discarded, the cells were washed twice with 2 mL of D-Hank's, and 1 mL of 0.25% trypsin was added (Gibco Company, Grand Island, NY, USA) for 2-5 min. The trypsin was removed, and 5 mL of DMEM containing 10% FBS was used to resuspend the cells for subsequent culture. The expression levels of FN1 among the five cell lines were detected by qRT-PCR. The two cell lines with the highest FN1 expression levels were then chosen for further experiments.
Cell transfection and grouping U251 and T98G cells at the logarithmic growth phase were selected for transfection. The cells were assigned to three groups: a blank group (cells with no transfection), a negative control (NC) group (cells transfected with empty vector) and an siRNA-FN1 group (cells transfected with siRNA-FN1-1, siRNA-FN1-2 Cellular Physiology and Biochemistry
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and siRNA-FN1-3, and the targeted plasmid with highest transfection efficiency was selected by qRT-PCR). All plasmids were purchased from the Sigma-Aldrich Chemical Company, St Louis MO, USA. Then, 6 µL of lipofectamine 2000 (Invitrogen Inc., Carlsbad, CA, USA) and 5 μg of plasmid were each diluted with 250 μL of serum-free Opti-MEM (Gibco Company, Grand Island, NY, USA), followed by incubation at room temperature for 5 min. The two dilutions were then mixed and incubated at room temperature for 20 min. The day before transfection, cells at logarithmic growth phase were inoculated into a 6-well plate at concentration of 1 × 10 6 cells/well. When confluency reached 60%, cell transfection was then performed. After a 6-h culture, the previous medium was replaced by complete medium, and after 48 h of transfection, the cells were collected.
Dual-luciferase reporter gene assay PI3K-Luc was regarded as the reporter gene of the PI3K/AKT signaling pathway. Thus, the effect of FN1 on the transcriptional activity of the PI3K/AKT signaling pathway was detected by a dual-luciferase reporter assay system (E1960, Promega Corp., Madison, Wisconsin, USA). The 4th generation of U251 cells was selected for the conventional culture process. The cells were then transfected with pGL3-basic and PI3K-Luc, as well as pGL3-FN1 and pRL-TK, when confluency was between 70% and 80%. After a 48-h period of transfection, the cells were washed with PBS and lysed using a PLB buffer. The samples were processed according to the instructions in the dual luciferase reporter gene assay kit (Promega Corp., Madison, Wisconsin, USA), and a fluorescence microplate reader (infinite M200, Tecan, Salzburg, Austria) was used to detect luciferase activity. The ratio of firefly luciferase activity to Renilla luciferase activity represents the transcriptional activity in PI3K/AKT signaling pathway.
3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) assay
Transfected cells were inoculated into a 96-well plate at concentration of 1 × 10 3 cells/well. Eight wells were used for each group, with 100 μL in each well. The cells were cultured in a 5% CO 2 incubator at 37°C. On days 1 through 6, 20 μL of 5 mg/mL MTT solution (5 mg/mL MTT, Sigma-Aldrich Chemical Company, St Louis MO, USA) was added to each well, followed by culture for 4 h. Afterwards, the culture medium was removed, and 150 μL of dimethyl sulphoxide (DMSO) was added, and the solution was incubated for 10 min. The optical density (OD) value of each well at 490 nm was detected by a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The experiment was repeated three times and the growth curves were drawn accordingly.
Flow cytometry
The transfected cells were washed twice with pre-cooled PBS and digested with 0.25% trypsin, and the density was adjusted with DMEM to 1 × 10 6 cells/mL. After fixing with pre-cooled 70% alcohol for 24 h, the cells were centrifuged at 1000 r/min for 5 min, followed by 2 washes with PBS. Next, 1 mL of propidium iodide (PI) (Sigma-Aldrich Chemical Company, St Louis MO, USA) containing RNase was added under dark conditions at 4°C. Cell cycle stages were detected by a flow cytometer (FACS Calibur, Becton, Dickinson and Company, New Jersey, USA). Each group had three replicates, and each process was repeated three times. Cell apoptosis was detected using the Annexin V-FITC/PI staining method. Next, 100 μL of 1 × 10 6 cells/mL cell suspension was added into 5 μL of Annexin V-FITC (C1063, Beyotime Biotechnology Co., Ltd. Shanghai, China) and 10 μL of PI, and the culture was incubated at room temperature for 15 min and washed twice with PBS. Cell apoptosis was analyzed using a flow cytometer at an excitation wavelength of 488 nm.
β-galactosidase staining
The transfected cells were inoculated into a 6-well plate. When the cell density reached 50%, the culture medium was removed, and the cells were washed with PBS. According to the instructions for the senescence-associated β-galactosidase (SA-β-gal, Cell Biolabs Inc., San Diego, CA, USA) detection kit, the cells were stained with 1 mL of SA-β-gal followed by incubation overnight at 37°C. SA-β-gal positive cells were observed to have a blue color. Five fields of view were randomly selected under an optical microscope and photographed to ascertain the positive cell count. The senescence index (SI) was calculated using the following formula: positive cells/total cells × 100%.
Scratch test
Cells were inoculated into a 6-well plate. When the cell density reached 90%, the medium was replaced by DMEM/0.1% FBS. The cell monolayers were scratched with a 10 μL sterile pipette tip along the central 
Transwell assay
Transfected cells in the logarithmic growth phase were resuspended in serum-free DMEM to 5 × 10 5 cells/mL. Then, 100 μL of the cell suspension was added to the Matrigel-coated upper chamber of the transwell (P01250, Millipore, Mass, USA), and 500 μL DMEM containing 10% FBS was added to the lower chamber. The cells were then cultured in a 5% CO 2 incubator for 24 h at 37°C The cells were stained with 1 mL of 0.1% crystal violet for 10 min, washed twice with PBS and dried at room temperature. The number of cells invading the membrane was then counted under a microscope. The experiment was repeated three times.
Statistical analysis
All experimental data were analyzed using the SPSS 21.0 software (IBM Corp. Armonk, NY, USA) and are presented as the mean ± standard deviation (SD). An independent sample's t test was used for comparison between two groups, while a paired t test for comparisons between glioma and normal brain tissues. A one-way analysis of variance (ANOVA) was used for comparisons among multiple groups. Discrete data values were expressed as either percentages or ratios and analyzed by chi-squared test. P < 0.05 was considered statistically significant.
Results
Identification of targeted gene
Among the top fifty regulated genes identified in profiling the glioma (GSE12657) and breast cancer (GSE15852) data, FN1 was confirmed to be the most significantly upregulated gene among both glioma and breast cancer (for all online suppl. material, see www.karger. com/doi/ 10.1159/000492096, Suppl. Fig. 1 ). Therefore, FN1 was selected for this study.
By analyzing the profiling data of the gliomas (GSE12657 and GSE15824), the expression of FN1 was higher in the glioma tissue than that in normal tissue (see online suppl. material, Suppl. Fig. 2 ). In the profile of GSE45921, significant differences were detected with regard to the expression of FN1 in gliomas with different pathological grades. The expression of FN1 was higher in high-grade gliomas than in low-grade gliomas (see online suppl. material, Suppl. Fig. 3 ).
GO enrichment analysis of DEGs
In the profile of GSE12657, FN1 was confirmed to be primarily involved in the synthesis of the basement membrane, the extracellular matrix (ECM) component and the basal lamina. The extracellular matrix played a role in molecular functioning, aiding in the binding of collagen and the regulatory activity of peptidase, as well as participating in the process of extracellular structure organization and endoderm development. (see online suppl. material, Suppl. Table 1~3) .
KEGG pathway enrichment analysis of DEGs
In the GSE12657 profile, the KEGG pathway enrichment analysis of DEGs revealed that FN1 was implicated in the ECM-receptor interaction pathway, the focal adhesion kinase (FAK) pathway, cell cycle-related pathways, small cell lung cancer-related pathways, the PI3K/ AKT signaling pathway, amoebiasisrelated pathways, protein processing pathways in the endoplasmic reticulum, t oxo p l a s m o s i s -re l a t e d pathways, pathways in cancer and the DNA replication-related pathway (see online suppl. material, Suppl. Table 4 ). The PI3K/ AKT signaling pathway displayed the greatest potential regarding a possible link to the occurrence and progression of glioma, while FN1 was related to the PI3K/AKT signaling pathway (see online suppl. material, Suppl. Fig. 4 ). FN1 was an important component of the ECM, as the upregulated expression of FN1 could lead to ECM deposition (see online suppl. material, Suppl. Fig. 5 ) and PI3K/AKT signaling pathway could be activated by ECM deposition to regulate the cell cycle (see online suppl. material, Suppl. Fig. 6 ). Therefore, it was speculated that FN1 was involved in the regulation of the cell cycle through the activation of the PI3K/AKT signaling pathway.
The protein expression of FN1 in glioma tissues and normal tissues
As shown in Fig. 1 , the FN1 protein was mainly expressed in the cytoplasm and stained a light brown or brown color. The positive rate of the FN1 protein was lower in normal tissues than in the glioma tissues (P < 0.05). No correlation was observed between the positive rate and factors such as the age or gender of patients with glioma (P > 0.05). However, significant correlations to tumor size and pathological grade of glioma were confirmed (P < 0.05). The positive expression of the FN1 protein was greater in high-grade gliomas than in low-grade gliomas. (P < 0.05) ( Table 2) . The mRNA and protein expression levels of FN1, PI3K, AKT, CDK4 and cyclin D1 were increased in glioma tissues compared to those in normal tissues (all P < 0.05), but the expression levesls of PTEN, pRb, p16 and p21 were decreased (all P < 0.05) (Fig. 2) . This finding suggested that aberrant activation of PI3K/AKT signaling pathway was present in glioma tissues.
FN1 gene expression among five cell lines (BT325, A172, U251, SHG44 and T98G)
Among the five glioma cell lines (BT325, A172, U251, SHG44 and T98G), the highest FN1 gene expression level was found in U251 and T98G cells (Fig. 3) . Therefore, these two cell lines were chosen for subsequent experiments.
Transfection efficiency for different siRNA-FN1
As shown in Fig. 4 , after transfection for 48 h, siRNA-FN1-1, siRNA-FN1-2 and siRNA-FN1-3 all exhibited gene-silencing effects. The lowest FN1 gene expression level was found in the siRNA-FN1-2 group, suggesting siRNA-FN1-2 possessed the highest efficiency. 
Figure 5
The activation of the PI3K/AKT signaling pathway by the FN1 gene Note: * P < 0.05, compared to the pGL3-basic group; FN1, fibronectin 1.
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FN1 activated PI3K/ AKT signaling pathway
Compared to the pGL3-basic group, the luciferase activity of the pGL3-FN1 group was increased in both the U251 and T98G cells (both P < 0.05) (Fig. 5) . The results showed that FN1 can activate the PI3K/AKT signaling pathway.
Expression levesls of the FN1 gene and related genes in the PI3K/AKT signaling pathway in U251 and T98G cells of each group
As illustrated in Fig. 6 , no statistical significance was observed with regard to the expressions of the FN1 gene, related genes in the PI3K/AKT signaling pathway and cell cycle-and cellular senescence-related genes in the U251 and T98G cells in both the blank group and the NC group (all P > 0.05). Compared to the blank and NC groups, the expression levels of FN1, PI3K, and AKT were all decreased in U251 and T98G cells in the siRNA-FN1 group, but the expression level of PTEN increased (all P < 0.05). These results suggest that FN1 gene silencing could inhibit the activation of the PI3K/AKT signaling pathway. Fig. 8 . Cell cycle stages and expression levels of cell cycle-related genes of U251 and T98G cells after transfection in each group. Note: A, cell cycle analysis of the U251 cells; B, cell cycle analysis of T98G cells; C, the mRNA expression levels of cell cycle-related genes in U251 cells of each group; D, the protein expression levels of cell cycle-related genes in U251 cells of each group; E, the mRNA expression levels of cell cycle-related genes in T98G cells of each group; F, the protein expression levels of cell cycle-related genes in T98G cells of each group; * P<0.05, compared to the blank and NC groups; FN1, fibronectin 1.
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Effect of siRNA-FN1 on cell proliferation in glioma cells
As presented in Fig. 7 , there was no statistical significance regarding the cell viability in U251 and T98G cells between the blank and NC groups (both P > 0.05). Compared to the blank and NC groups, cell viability in the U251 and T98G cells of the siRNA-FN1 group decreased (both P < 0.05). These results suggest that FN1 gene silencing can inhibit cell proliferation in glioma cells. 
Effect of siRNA-FN1 on the cell cycle and the expression of cell cycle-related genes in glioma cells
There was no statistical significance observed in terms of cell cycle distribution in the U251 and T98G cells between the blank and NC groups (all P > 0.05). However, compared to that in the blank and NC groups, the number of cells in the G1 phase was increased, while in the siRNA-FN1 group the number of cells in S phase was decreased (all P < 0.05) (Fig. 8) . The results of qRT-PCR and Western blot analysis suggested that there was no significant difference in the expression of cell cycle-related genes (pRb, CDK4, and cyclin D) between the blank and NC groups (all P > 0.05). The mRNA and protein expression levels of CDK4 as well as cyclin D were notably decreased, and pRb expression was increased in the siRNA-FN1 group compared to that in the blank and NC groups (all P < 0.05). These data suggest that FN1 gene silencing can arrest glioma cells in G1 phase through the regulation of the expressions of cell cycle-related genes.
Effect of siRNA-FN1 on cell apoptosis in glioma cell U251 and T98G cell lines in each group displayed similar trends regarding cell apoptosis. There was no statistical significance detected in relation to cell apoptosis between the blank group and the NC group (P > 0.05). However, the cell apoptotic rate was notably increased in the siRNA-FN1 group compared to the blank and NC groups (all P < 0.05) (Fig. 9) . The results indicated that FN1 gene silencing can promote cell apoptosis in glioma cells.
Effect of siRNA-FN1 on cell senescence and the expression of cell senescence related genes in glioma cell
As shown in Fig. 10 , the U251 and T98G cell lines in each group displayed similar trends in relation to cell senescence. There was no significant difference observed in terms of cell senescence and the expressions of cell senescence-related genes (p16 and p21) between the blank group and the NC group (P > 0.05). Compared to that in the blank and NC groups, the cell senescence rate was notably increased in the siRNA-FN1 group, and the expression levels of p16 and p21 were significantly elevated (all P < 0.05). The results indicated that FN1 gene silencing can promote glioma cell senescence through regulating the expression of cell senescence-related genes. Fig. 11 shows that no statistical significance was found regarding cell migration and invasion abilities in U251 and T98G cells between the blank group and the NC group (all P > 0.05). The ability of cell migration and invasion in U251 and T98G cells of the siRNA-FN1 
Effect of siRNA-FN1 on cell migration and invasion in glioma cells
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Cellular Physiology and Biochemistry group was reduced compared to the blank and NC groups (all P < 0.05). The results reflected that FN1 gene silencing could suppress cell migration and invasion in glioma cells.
Discussion
Glioma represents one of the most commonly occurring brain tumors. It is highly aggressive in nature and has a considerably poor prognosis. Over the past few decades, great strides have been made in regard to the progression of therapies targeting glioma through the use of various drug delivery systems. An improved understanding of the molecular mechanism of tumors can aid in the development of effective therapies. In the current study, we focused on the FN1 gene, its regulation of glioma cells and its involvement in the PI3K/ AKT signaling pathway. Our results demonstrated that the FN1 gene can control the cell cycle and inhibit cell senescence and apoptosis in human glioma cells through the activation of the PI3K/AKT signaling pathway.
Initially, we reviewed the expression profiles of gliomas (GSE12657, GSE15824 and GSE45921), and, based on GEO data sets analysis, successfully identified the FN1 gene as the most significantly upregulated gene in glioma. Furthermore, we found that FN1 is involved in the synthesis of ECM components and PI3K/AKT signaling pathway. Microarray expression data of gliomas revealed molecular subtypes as well as genes associated with tumor grade, development and patient survival [21] [22] [23] . Studies have reported that the predicted outcome of microarray expression data to be superior to that of the more traditional histological criteria [24, 25] . A previous study documented that the expression of tumor-related FNs is markedly higher than that of normal tissue-related FNs in breast cancer [26] , and the high expression of FN in glioma cells before anticancer drug-treatment [27] . This elevated degree of richness may contribute to the tumor-targeting efficiency when FN functions are the therapeutic target [28] . FN is a ubiquitous ECM glycoprotein that is assembled into a fibrillar matrix in all tissues throughout a person's lifetime. The substantial amount of ECM in the glioma microenvironment is of importance in the maintenance of glioma morphology and is associated with glioma cell proliferation and differentiation [29] [30] [31] . Reports have indicated that the PI3K/AKT/mTOR pathway is instrumental in FN transcription and alternative splicing, which modulates cell behavior [32] . Matsuo et al. reported that the PI3K/AKT pathway is activated by FN with the aid of integrin αv-mediated a disintegrin and metalloprotease (ADAM) activity in hepatocellular carcinoma [33] . In the present study, the results of obtained from immunocytochemistry, qRT-PCR and Western blotting methods all revealed the upregulation of both FN1 and PI3K/AKT pathway-related genes and proteins in glioma.
To further explore the functions of the FN1 gene, siRNA plasmids of FN1 were transfected into glioma cells. The results revealed that in U251 and T98G cells, FN1 gene silencing could inhibit cell proliferation, promote cell senescence and apoptosis, and reduce migration and invasion through PI3K/AKT signaling pathway disruption. The glioma cell lines were shown to synthesize FN, a non-collagenous glycoprotein associated with basal lamina. FN has been implicated in the development of multiple human cancers and is associated with increased tumor cell migration and invasion in metastatic models [34] . A pivotal factor during tumor cell invasion is the interaction of neoplastic cells with the ECM. This process involves specific cell surface receptors including, among others, the hyaluronan receptor CD44 as well as integrins [35] . Extracellular FN is a ligand for integrins, which control biological and cellular functions such as cell adhesion, invasion, differentiation, proliferation and apoptosis in both normal and cancer cells. In this regard, integrin β 1 was shown to be a major cell surface receptor in glioma and to facilitate its progression [36, 37] . Moreover, Sengupta et al. specifically demonstrated that the short hairpin RNA-mediated silencing of FN expression in glioma cells delayed cell proliferation in vitro [36] . FN is known to activate diverse signaling pathways by activating intracellular second messenger systems and regulating the activities of several growth factors and proteins [38] . AKT signaling pathway is involved in the promotion of senescence and apoptosis and the reduction of the viability and migration of glioma cells using quercetin [27] . A recent study has further demonstrated a virus-mediated siRNA targeting the p85 subunit of PI3K and AKT1 exhibited opposite effects on the invasion and proliferation of U251 glioma cells [39] . Collectively, the key finding of this study was that FN1 can act as a regulator of glioma cells activity. The suppression of the FN1 gene results in suppressed cell proliferation, increased cellular senescence, apoptosis and reduced migration and invasion through blocking the activation of the PI3K/AKT signaling pathway. Our findings demonstrated the pivotal role that the FN1 gene plays in the progression of glioma, ultimately suggesting that it could serve as a therapeutic target in glioma management. However, we studied a small sample, and further larger-scale studies are needed to validate this clinical utility.
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